Filter
1764
Filtered Results: 1764
Text search:
COVID-19
emergency
response
Featured
Recommendations
195
New Publications
30
Language
Document type
Studies & Reports
647
Guidelines
452
Strategic & Response Plan
196
Manuals
145
Fact sheets
127
Situation Updates
98
Training Material
31
No document type
31
Infographics
20
Resource Platforms
11
Brochures
3
Online Courses
2
Videos
1
Countries / Regions
Global
148
Latin America and the Carribbean
66
Syria
54
Ukraine
54
Africa
46
India
39
Brazil
38
Middle East and North Africa
37
Western and Central Europe
35
East and Southern Africa
33
Kenya
32
Yemen
31
Russia
29
Ethiopia
27
West and Central Africa
27
South–East Asia Region
26
South Africa
25
South Sudan
24
Eastern Europe and Central Asia
22
Nigeria
20
Congo, Democratic Republic of
20
Malawi
17
Mozambique
17
Venezuela
17
Bangladesh
16
Haiti
15
Myanmar / Burma
14
Afghanistan
13
Western Pacific Region
13
Sudan
12
Philippines
11
Germany
11
Central African Republic
11
Senegal
10
Somalia
10
Pakistan
9
Colombia
9
Ghana
8
Uganda
8
Angola
8
Chile
8
Eastern Europe
8
Burkina Faso
7
Niger
7
Zambia
7
Moldova
7
Iraq
6
Jordan
6
Lebanon
6
Thailand
6
Rwanda
6
Palestine
6
Laos
6
Liberia
5
Mali
5
Côte d’Ivoire / Ivory Coast
5
Zimbabwe
5
Nepal
5
Turkey
5
Tanzania
5
China
5
Argentina
5
Vietnam
5
Sierra Leone
4
Guinea-Bissau
4
Indonesia
4
Namibia
4
Ecuador
4
Libya
4
Lesotho
4
Mexico
4
Iran
4
Cameroon
3
Cambodia
3
Peru
3
Burundi
3
Paraguay
3
Asia
3
Italy
3
Tajikistan
3
Uzbekistan
3
Jamaica
3
Tunisia
3
United Kingdom
3
Portugal
3
Spain
3
Guinea
2
Egypt
2
Chad
2
Malaysia
2
Papua New Guinea
2
Eswatini/ Swaziland
2
Hungary
2
Bolivia
2
Poland
2
Armenia
2
Bulgaria
2
Romania
2
Kyrgyzstan
2
Kazakhstan
2
North America
2
Turkmenistan
2
Japan
2
Mauritius
2
Morocco
1
USA
1
Togo
1
Gambia
1
Mauritania
1
North Macedonia
1
Serbia
1
Botswana
1
El Salvador
1
Madagascar
1
Sri Lanka
1
Fiji
1
Djibouti
1
Mongolia
1
Timor Leste/ East Timor
1
Slovakia
1
Georgia
1
Gabon
1
France
1
Morocco
1
Belarus
1
Israel
1
Authors & Publishers
Publication Years
Category
Countries
714
Public Health
79
Key Resources
66
Clinical Guidelines
59
Women & Child Health
52
Pharmacy & Technologies
19
Capacity Building
13
Annual Report MEDBOX
1
Toolboxes
COVID-19
941
Planetary Health
111
Conflict
107
Refugee
55
HIV
54
Mental Health
50
Caregiver
46
Health Financing Toolbox
46
Rapid Response
45
Global Health Education
32
Natural Hazards
31
AMR
28
NCDs
24
TB
17
Pharmacy
13
Disability
12
NTDs
10
Ebola
7
Cholera
5
Polio
4
Zika
3
Social Ethics
2
Specific Hazards
1
WHY THIS GUIDE?
Because, in the face of crises and emergencies, it is vital to include a human rights perspective in responses. Vulnerable groups face major obstacles to accessing and benefiting from prevention, mitigation, and health care policies...
The World Health Organization Regional Office for Africa (WHO AFRO), in accordance with recommendations from various WHO committees, has developed three flagship programmes to support Member States in the African region to prepare for, detect and respond to public health emergencies. They are the re...
Contact tracing is a key element of WHO’s recommended approach to control the spread of COVID-19 by breaking the chains of human-to-human transmission.
This document provides guidance to health a...
The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological
situation of the COVID-19 pandemic as of 21 January 2022 – at a time wh...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-.... This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
Временное руководство23 декабря 2020 г.
Produced by Training and Research Support Centre for the Regional Network for Equity in Health in east and southern Africa (EQUINET), March 20, 2020.
This brief summarises and provides links to official, scientific and other resources to support an understanding of and individual to regional level...
NAMI HelpLine
Contents
I’m having a lot of anxiety because of the coronavirus. Please help.
I’m quarantined or working from home – lonely and isolated even further – what can I do?
I don’t have health insurance or a regular doctor – how can I get care?
What if I’m quarantin...
On 31st December 2019, the World Health Organization (WHO) China Country Office was informed of cases of pneumonia of unknown etiology (unknown cause) detected in Wuhan City, Hubei Province of China. On 7th January 2020, Chinese authorities identified a new strain of Coronavirus as the causative age...
April 2020
This Guidance Note offers a list of recommendations based on a combination of WHO guidelines, good practice and expert advice based on the latest scientific research. The situation with COVID-... is evolving rapidly and the guidance will continue to be updated if and when new evidence or information becomes available.
9 April 2020
WHO has published the guidance “Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected” This document is intended for clinicians taking...
Throughout the gestational period, it is important for obstetric health care facilities to strengthen health counselling, screening, and follow-ups for pregnant women, while incorporating screening, hand hygiene practice, good respiratory etiquette and infection prevention control precautions. These...
This document updates the earlier version published in April 2020. In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 ha...
This policy paper underscores that, although children do not represent a high-risk group for direct COVID-19 fatality, the pandemic posts far-reaching secondary impacts that heighten risks to Africa...
In Israel, as in other countries, the COVID-19 outbreak highlights existing structural inequities,which compromise the health of some migrant groups. The Israeli case also demonstrate show strong NG...
